公开(公告)号：US20210239682A1

公开(公告)日：2021-08-05

申请号：US17216926

申请日：2021-03-30

Applicant: Kyoto University ,  Megakaryon Corporation

Inventor： Koji Eto ,  Hideya Seo ,  Akira Ota ,  Yukitaka Ito ,  Yasuko Hazama

IPC: G01N33/50 ,  C12N15/09 ,  C12Q1/6897 ,  C12N15/10

Abstract: The present invention provides a method for screening for platelet production promoters, the method including a step for selecting a candidate substance that significantly increases expression of TUBB1 as a platelet production promoter.

公开(公告)号：US20210230311A1

公开(公告)日：2021-07-29

申请号：US17225273

申请日：2021-04-08

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Junichi NEZU ,  Atsushi Narita ,  Takahiro Ishiguro ,  Mika Sakurai ,  Hirotake Shiraiwa ,  Naoka Hironiwa ,  Tomoyuki Igawa ,  Yumiko Kawai

IPC: C07K16/46 ,  C12N15/09 ,  C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  C12N5/10

Abstract: Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.

公开(公告)号：US20210214801A1

公开(公告)日：2021-07-15

申请号：US17114210

申请日：2020-12-07

Applicant: TORAY INDUSTRIES, INC. ,  NATIONAL CANCER CENTER

Inventor： Junpei KAWAUCHI ,  Hitoshi NOBUMASA ,  Satoko KOZONO ,  Satoshi KONDOU ,  Hiroko SUDO ,  Atsushi OCHIAI ,  Motohiro KOJIMA

IPC: C12Q1/6886 ,  C12M1/00 ,  C12M1/34 ,  C12N15/09 ,  G01N37/00 ,  G01N33/53 ,  G01N33/574

Abstract: This invention provides a kit or a device for the detection of pancreatic cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting pancreatic cancer, comprising measuring the miRNA(s) in vitro.

公开(公告)号：US11060056B2

公开(公告)日：2021-07-13

申请号：US15776317

申请日：2016-08-04

Applicant: Rajendra Surana

Inventor： Rajendra Surana ,  Shashikant Shingdilwar ,  Pushpa Agrawal

IPC: C12N1/18 ,  C12P7/06 ,  C12N15/09 ,  C12P7/10

Abstract: The present invention relates to a modified yeast strain of Saccharomyces cerevisiae having MCC accession number 0069 with osmo-tolerant, thermo-tolerant, ethanol tolerant and self-flocculation properties. Further, the present invention relates to a method for obtaining modified yeast strain. The present invention also relates to a method of production of ethanol at high temperature using said yeast strain. The ethanol produced by the method disclosed in the present invention is used as fuel.

公开(公告)号：US20210207093A1

公开(公告)日：2021-07-08

申请号：US17189243

申请日：2021-03-01

Applicant: Precision BioSciences, Inc.

Inventor： Derek Jantz ,  James Jefferson Smith ,  Michael G. Nicholson ,  Daniel T. MacLeod ,  Jeyaraj Antony ,  Victor Bartsevich

IPC: C12N5/0783 ,  A61K39/00 ,  A61K35/17 ,  C12N15/09 ,  C12N15/113 ,  C12N15/86 ,  A61K48/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30 ,  C07K16/28

Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.

公开(公告)号：US11045534B2

公开(公告)日：2021-06-29

申请号：US16088682

申请日：2017-03-27

Applicant: TORAY INDUSTRIES, INC.

Inventor： Takayuki Fujita ,  Fumiyoshi Okano

IPC: A61K39/395 ,  A61K39/00 ,  C07K14/54 ,  C07K14/555 ,  C07K14/705 ,  C12N15/09 ,  A61K31/7088 ,  A61K38/00 ,  A61K35/76 ,  A61K38/21 ,  A61P35/00

Abstract: The present application relates to a novel immunity-inducing agent for treatment and/or prevention of cancer. Specifically, the present application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from polypeptides derived from MCEMP1 and modified forms thereof, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo, and a method for inducing immunity, comprising administering the immunity-inducing agent to a subject.

公开(公告)号：US11041152B2

公开(公告)日：2021-06-22

申请号：US16092830

申请日：2017-04-13

Applicant: e-NA Biotec Inc. ,  Yukihiro Akao ,  Yukio Kitade

Inventor： Yukihiro Akao ,  Yukio Kitade ,  Mitsuaki Sekiguchi ,  Yasunori Mitsuoka ,  Akira Kugimiya ,  Yasuo Sasaki

IPC: C12N15/113 ,  C12N15/09 ,  A61K48/00 ,  A61K31/713 ,  A61P35/00 ,  C07H21/02

Abstract: The purpose of the present invention is to provide novel miR-143 derivatives described herein that can be used as oligonucleotide therapeutics.

公开(公告)号：US11041146B2

公开(公告)日：2021-06-22

申请号：US15523571

申请日：2015-03-30

Applicant: Masakazu Kurita

Inventor： Masakazu Kurita

IPC: C12N5/10 ,  A61K35/12 ,  A01K67/027 ,  C12N15/09 ,  C12N15/00 ,  G01N33/50 ,  C12N5/077 ,  C12N5/071 ,  A61K48/00 ,  C12M1/00 ,  C12Q1/02 ,  G01N33/15

Abstract: To convert directly from a somatic cell into a cell having the ability to form stratified epithelial tissue that can act as outer skin of the body, a method for producing a cell having the ability to form stratified epithelial tissue is provided, the method including the step of introducing into a somatic cell at least one gene expressed relatively strongly in a cell having the ability to form stratified epithelial tissue.

公开(公告)号：US11041014B2

公开(公告)日：2021-06-22

申请号：US16344875

申请日：2017-10-27

Applicant: S & K BIOPHARMA, INC.

Inventor： Atsushi Sato ,  Shinji Kagaya

IPC: C07K14/79 ,  C12N15/62 ,  C12N15/82 ,  C07K14/765 ,  A61P35/00 ,  A61K38/40 ,  C12N5/10 ,  C12P21/02 ,  A61P43/00 ,  A61P39/04 ,  C07K19/00 ,  A61K38/38 ,  A61P9/10 ,  C12N15/09 ,  A01K67/027

Abstract: The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of native lactoferrin while having a significantly extended in vivo life span, and that has more clinical utility than native lactoferrin and recombinant lactoferrin; and a production method therefor. With this fusion protein or a variant thereof, the ability of lactoferrin to bind iron is retained, and therefore at least the important biological activity of lactoferrin that is based on the iron-binding ability is retained. Additionally, this fusion protein or variant thereof has bioavailability and resistance to protease, and thus can exhibit biological activity in vivo over a long period. Furthermore, this fusion protein is not easily broken down by pepsin in the stomach.

公开(公告)号：US20210155662A1

公开(公告)日：2021-05-27

申请号：US17161456

申请日：2021-01-28

Applicant: Avidity Biosciences, Inc.

Inventor： Hanhua HUANG ,  Rob BURKE

IPC: C07K14/47 ,  C12N15/113 ,  C12N15/09 ,  C12Q1/68 ,  C12Q1/686

Abstract: Disclosed herein are molecules and pharmaceutical compositions that mediate RNA interference against MYC. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that mediate RNA interference against MYC.